Managed Account Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Managed Account Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$680K	Sell	5,672 -2,049	-27%	-$245K	﹤0.01%	2223
2015 Q1	$806K	Sell	7,721 -1,612	-17%	-$163K	﹤0.01%	2151
2014 Q4	$906K	Sell	9,333 -17,681	-65%	-$1.64M	﹤0.01%	2089
2014 Q3	$2.11M	Buy	27,014 +23,235	+615%	+$1.5M	﹤0.01%	1785
2014 Q2	$239K	Sell	3,779 -3,189	-46%	-$190K	﹤0.01%	2264
2014 Q1	$468K	Buy	6,968 +2,235	+47%	+$173K	﹤0.01%	2111
2013 Q4	$304K	Buy	4,733 +1,107	+31%	+$66K	﹤0.01%	2136
2013 Q3	$232K	Sell	3,626 -977	-21%	-$48.7K	﹤0.01%	2116
2013 Q2	$143K	Buy	+4,603	New	+$122K	﹤0.01%	2187

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Managed Account Advisors's ALNY Position: Q2 2015 in Review

Managed Account Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 27% in Q2 2015, selling an estimated $245K and leaving 5,672 shares worth $680K. The position accounts for ﹤0.01% of the portfolio, ranked #2223.

Managed Account Advisors first reported a position in ALNY in Q2 2013 and has held it in 9 quarters since. The position peaked at $2.11M in Q3 2014. 278 funds tracked by Wall St. Rank hold ALNY as of Q2 2015.

Managed Account Advisors held 5,672 shares of Alnylam Pharmaceuticals worth $680K as of Q2 2015.
Managed Account Advisors sold 2,049 Alnylam Pharmaceuticals shares in Q2 2015, an estimated $245K.
Alnylam Pharmaceuticals made up ﹤0.01% of Managed Account Advisors's portfolio in Q2 2015, its #2223 holding.
Managed Account Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 9 quarters since.
Managed Account Advisors's Alnylam Pharmaceuticals position peaked at $2.11M in Q3 2014.
278 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.